Results 191 to 200 of about 22,482 (226)

Outcomes of Intravitreal Aflibercept 8 mg in Eyes With Neovascular Age-Related Macular Degeneration Previously Treated With Faricimab.

Ophthalmic Surgery Lasers and Imaging Retina
BACKGROUND AND OBJECTIVE To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab.
Bita Momenaei, Yoshihiro Yonekawa, Paige Abril, Rachel McCullough, A. Abbey   +4 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly, 2017
  +7 more sources

Aflibercept

Reactions Weekly, 2019
  +8 more sources

Aflibercept

Reactions Weekly, 2021
  +4 more sources

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

Investigative Ophthalmology and Visual Science
Purpose To assess the anatomic and functional outcomes in eyes with diabetic macular edema (DME) switched from intravitreal aflibercept to faricimab in a real-world setting. Methods Retrospective, interventional consecutive case series. Patients with DME
K. L. Huber, H. Stino, I. Steiner, Philipp Fuchs, Felix Goldbach, Julia Mai, B. Gerendas, K. Kriechbaum, Ursula Schmidt-Erfurth, A. Pollreisz   +9 more
semanticscholar   +1 more source

Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared to Originator Product in Patients with Neovascular Age-related Macular Degeneration.

Ophthalmology Retina
OBJECTIVE To assess the non-inferiority of biosimilar aflibercept (CinnaGen Company, Iran) (P041) to the originator aflibercept (Regeneron, US) (AFL) in terms of efficacy, safety, and immunogenicity.
R. Karkhaneh, H. Faghihi, H. Riazi-Esfahani, M. Abrishami, F. Bazvand, Nazanin Ebrahimiadib, Mohammadkarim Johari, Mohammadreza Akhlaghi, Nasser Shoeibi, Mohammad Hossein Norouzzadeh, Mohammad Reza Ansari Astaneh, Hassan Khojasteh, Marjan Imani Fooladi, A. Khodabande, Fariba Ghassemi, Elias Khalili pour, M. Zarei, A. Mirshahi, F. Fazel, Hossein Ashraf, S. Hosseini, Maryam Dourandeesh, Mostafa Feghhi, Yousef Alizadeh, Hassan Behboudi, Pejvak Azadi, Araz Sabzvari, Hamidreza Kafi, Khalil Ghasemi Falavarjani   +28 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly, 2023
  +4 more sources

Aflibercept

Reactions Weekly, 2016
  +4 more sources

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

Cancer Medicine
Sapanisertib is a potent ATP‐competitive, dual inhibitor of mTORC1/2. Ziv‐aflibercept is a recombinant fusion protein comprising human VEGF receptor extracellular domains fused to human immunoglobulin G1.
Niamh Coleman, B. Stephen, S. Fu, D. Karp, V. Subbiah, J. Ahnert, S. Piha-Paul, John Wright, S. Fessahaye, Fengying Ouyang, Bulent Yilmaz, F. Meric-Bernstam, A. Naing   +12 more
semanticscholar   +1 more source

Aflibercept

Reactions Weekly, 2018
  +5 more sources